Guanine | Investors

⭐ Why Investors Care

Why Architecture Matters to the Business

Infrastructure Economics

Hardware-bound diagnostics scale linearly with cost
Software-defined architectures scale exponentially
One sensing engine supports many markets and products
OEM partners can rehost biomarkers without rebuilding infrastructure

Guanine is positioned as infrastructure, not a single diagnostic product.

Why Software-Defined Matters to Investors

No optical stacks, lasers, or spectral scaling costs
Faster iteration cycles than hardware-locked competitors
OEM licensing scales without manufacturing bottlenecks
Software leverage increases margins over time

Scale comes from configuration—more assays and partners, not more hardware complexity.

⭐ Market Expansion Logic

One Infrastructure → Many Diagnostic Businesses

Investors should not read this as “sepsis first, then maybe more.” Sepsis is the proving ground for the architecture—chosen because it is the highest-cost, most time-critical clinical window where speed, breadth, and phenotypic confirmation must converge.

Sepsis

→

OEM Diagnostics

→

Pharma / CDx / TDM

→

Multi-omic AI Data

Expansion Path

Initial wedge: sepsis (highest-cost, most time-critical condition)
Platform expansion: OEM diagnostics, pharma, CDx, TDM, AI health
Partner scaling: rehost biomarkers without rebuilding instruments

Revenue Streams

Instruments (reader platforms)
Cartridges & consumables
Software & analysis layers
OEM licensing & developer kits

Sepsis is the proof point—architecture is the business.

⭐ IP & Defensibility

Architectural Lock-In, Not Just Novelty

Guanine’s defensibility is rooted in a molecular signal layer and software–hardware co-design. This is not replicable by “adding software” to legacy instruments—because the signal primitive itself is molecular and reversible.

Core Moats

Reversible quadruplex tags → stable signal primitives
CME → multiplexing scalability
MDWC → signal separation moat
Software–hardware co-design → high switching costs

Why Switching Costs Rise

Assay menus scale within a shared sensing layer
Performance improves via software updates and waveform control
Partner biomarkers can be rehosted without new instrument stacks
Platform learning compounds across assays, matrices, and workflows

Defensibility compounds as the platform scales—across assays, partners, and data.

⭐ Diligence & Trust

Technical & IP Transparency

Granted Patents

Non-Confidential Materials

Peer-Reviewed Publications

Upon Request

Non-confidential architecture materials for initial review
Deeper technical diligence under NDA
Partner evaluation packages for strategic collaborators

Built for institutional diligence, strategic partnerships, and long-term scale.

Request a Pitch Deck Review the Architecture OEM Partnership Overview

⭐ Why Now

The Diagnostic Landscape Has Shifted—Permanently

Guanine is purpose-built for this new diagnostic reality: time-critical decisions, rising system costs, and a growing need for dense, quantitative multi-omic data.

Clinical Drivers

Sepsis and AMR require rapid, actionable data
Drug susceptibility must move beyond culture
Clinicians need integrated host–pathogen–phenotype insight

Economic Drivers

Hospitals face severe cost and staffing pressures
Diagnostics must move closer to the patient and reduce burden

OEM & Data Drivers

Optical platforms are hitting hard multiplexing limits
OEMs want scalable assay menus without rebuilding stacks
AI requires rich, quantitative multi-omic data

A New Diagnostic Architecture for a Data-Driven Healthcare Era